BRIEF published on 04/22/2026 at 22:10, 3 days 1 hour ago Abivax unveils key data on obefazimod at Digestive Disease Week Abivax Obefazimod Ulcerative Colitis Clinical Trials Digestive Disease Week
BRIEF published on 04/22/2026 at 22:10, 3 days 1 hour ago Abivax to Present Data on Obefazimod at Digestive Disease Week® Abivax Obefazimod Ulcerative Colitis Phase 3 Clinical Trials DDW 2026
PRESS RELEASE published on 04/22/2026 at 22:05, 3 days 1 hour ago Abivax to Present Data on Obefazimod at Digestive Disease Week® Abivax to present data on Obefazimod at Digestive Disease Week, showcasing efficacy, safety, and patient outcomes from Phase 3 ABTECT program and preclinical anti-fibrotic models Abivax Obefazimod Clinical Trials Digestive Disease Week Inflammatory Bowel Disease
BRIEF published on 04/20/2026 at 22:10, 5 days 1 hour ago Abivax: Annual General Meeting scheduled for May 11, 2026 Biotechnology Abivax Obefazimod General Assembly Preparatory Documents
BRIEF published on 04/20/2026 at 22:10, 5 days 1 hour ago Abivax Prepares for General Meeting with Document Release Biotechnology Abivax Ulcerative Colitis General Meeting Preparatory Documents
PRESS RELEASE published on 04/20/2026 at 22:05, 5 days 1 hour ago Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents Abivax informs shareholders about the Annual Ordinary and Extraordinary General Meeting on May 11, 2026, in Paris, providing access to preparatory documents Shareholders Abivax General Meeting Clinical-stage Biotechnology Preparatory Documents
BRIEF published on 04/17/2026 at 15:48, 8 days 7 hours ago JP Morgan Chase & Co. crosses the 5% threshold in ABIVAX Voting Rights Abivax Threshold Crossing JP Morgan Indirect Ownership
BRIEF published on 04/17/2026 at 10:42, 8 days 12 hours ago JP Morgan Chase & Co. reduces its stake in ABIVAX Euronext Paris Voting Rights Abivax Threshold Crossing JP Morgan
BRIEF published on 04/08/2026 at 12:17, 17 days 11 hours ago Abivax presents the results of the ABTECT trial Abivax Obefazimod Ulcerative Colitis Clinical Trial Tolérance
BRIEF published on 04/01/2026 at 22:10, 24 days 1 hour ago Abivax submits its financial reports to French and American regulators AMF Abivax Financial Reports Regulation DRY
Published on 04/25/2026 at 03:10, 20 hours 16 minutes ago BEACN Announces Financial Results for Year Ended December 31, 2025
Published on 04/24/2026 at 22:05, 1 day 1 hour ago Critical Elements Mourns the Loss of Director Marc Simpson
Published on 04/24/2026 at 22:00, 1 day 1 hour ago Kidoz Inc. to Present 2025 Results and Highlight Platform Expansion and Business Momentum
Published on 04/24/2026 at 15:00, 1 day 8 hours ago Norsemont Reports Significant Copper, Lead & Zinc Values in Three Choquelimpie Drill Holes
Published on 04/24/2026 at 15:00, 1 day 8 hours ago First Canadian Graphite Appoints Scott Kelly As Chief Financial Officer
Published on 04/25/2026 at 16:25, 7 hours 1 minute ago Leading a New Era of Family Mobility! CHERY TIGGO V, the 3-in-1 Family Vehicle, Debuts at AutoChina2026
Published on 04/24/2026 at 22:43, 1 day ago EQS-Adhoc: Marley Spoon Group SE: Closing of the financing transaction in connection with the financial restructuring of its German subsidiary Marley Spoon SE with increased financing amou
Published on 04/24/2026 at 22:05, 1 day 1 hour ago Berlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study
Published on 04/24/2026 at 18:12, 1 day 5 hours ago EQS-Adhoc: clearvise AG reviews dividend proposal in line with its dividend strategy and postpones Annual General Meeting
Published on 04/24/2026 at 18:07, 1 day 5 hours ago DEAG sets new records for revenue and earnings in financial year 2025 – excellently positioned for long-term growth
Published on 04/24/2026 at 17:45, 1 day 5 hours ago Imerys-04-2026-information-share-capital-and-voting-rights-as-of-31-March-2026
Published on 04/24/2026 at 16:37, 1 day 6 hours ago Availability of the 2025 Universal Registration Document (URD)
Published on 04/23/2026 at 19:27, 2 days 3 hours ago Annual Shareholders' Meeting 2026 - Conditions of availability of the preparatory documents
Published on 04/23/2026 at 18:18, 2 days 5 hours ago Aéroports de Paris SA - Sale by Groupe ADP of securities representing 3.4% with option to sell an additional 3.9% of GAL's equity share capital to GMR Group
